Drug industry
Article Abstract:
The drug industry did well in the second quarter 1996, and stock performance is also good with steady earnings. Nine of ten prescription drug companies saw their stocks increase. Several individual companies should be considered as investments in the long- and short-term. Careful consideration must be given to the individual performances and outlook for individual sectors.
Author: Clark, Charles, Butler, Jeremy J., Markey, Keith A., Ferguson, Keith E., Rho, George I. H., Maher, John E.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1996
Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Drugs, Pfizer Inc., Pharmacia and Upjohn Inc., PNU, Warner-Lambert Co., SmithKline Beecham Group PLC, Perrigo Co., Schering-Plough Corp., PRGO, PFE, SGP, WLA, Genetics Institute Inc., GENI, Rhone-Poulenc Rorer Inc., Roberts Pharmaceutical Corp., RPCX, R.P. Scherer Corp., RPR, SHR
Drug industry
Article Abstract:
Drug industry stocks have major, dependable earnings with potential for growth over the long term. These companies are also not susceptible to the Asian economic crisis or fluctuations in economic cycles. Drug stocks have performed well between 1994 and 1997. US drug industry sales are still strong in 1998 with growth expected in new products and volume.
Author: Rho, George, Mitkowski, Robert, Jr., Ferro, Mario, Romaine, Sigourney B., Schlein, Milton, Feenan, Gerard, Harris, Frederick L., III, Clark, Charles, Gallen, David, Butler, Jeremy J., Markey, Keith A., Gagas, Adam C., Owens, Victoria
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1998
Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Monsanto Co., MTC, Block Drug Company Inc., Dura Pharmaceuticals Inc., Human Genome Sciences Inc., Jones Pharma Inc., BRL, BLOCA, DURA, HGSI, JMED, Agouron Pharmaceuticals Inc., AGPH, Barr Laboratories Inc.
Subjects list: Economic aspects, Pharmaceutical industry, Drugs, Finance, Eli Lilly and Co., Glaxo Wellcome PLC, Genentech Inc., Biogen Inc., Bristol-Myers Squibb Co., ALZA Corp., Amgen Inc., Chiron Corp., Cygnus Inc., Forest Laboratories Inc., Genzyme Corp., Immunex Corp., IVAX Corp., Mylan Laboratories Inc., Sicor Inc., AZA, AHP, AMGN, BGEN, BMY, CHIR, FRX, GENZ, ICN, IMNX, IVX, LLY, MLY, GNE, Valeant Pharmaceuticals International, Wyeth, Merck & Company Inc., GNSA
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
